Doering, E.
Hoenig, M. C.
Bischof, G. N.
Bohn, K. P.
Ellingsen, L. M.
van Eimeren, T.
Drzezga, A.
,
Funding for this research was provided by:
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
Article History
Received: 12 January 2022
Accepted: 14 June 2022
First Online: 14 July 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki and ICH/GCP guidelines. Approval was granted by the Ethics Committee of the Technical University of Munich (EUDRACT 2006–000762-36). Informed consent was obtained from all individual participants included in the study.
: TvE reported receiving consulting and lecture fees from Lundbeck A/S, Lilly Germany, and Shire Germany and research funding from the German Research Foundation (DFG), the Leibniz Association, and the EU-joint program for neurodegenerative disease research (JPND). AD reported receiving research support and speaker honoraria by Life Molecular Imaging, AVID/Lilly Radiopharmaceuticals, Siemens Healthineers, and GE Healthcare. No other disclosures were reported.